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Abstract
Objective
To assess the utility of QuantiFERON®-TB Gold In-tube (QFT-GIT) for targeting preventive
therapy in BCG-vaccinated contacts of tuberculosis (TB), based on its high specificity and
negative predictive value for development of TB.
Methods
We compared two screening strategies for TB contact tracing in two consecutive periods: the
tuberculin skin test (TST) period, when all contacts were screened with the TST alone; and
the QFT-GIT period, when BCG-vaccinated contacts underwent TST and QFT-GIT. Diagno-
sis of TB infection among BCG-vaccinated contacts relied on TST5 mm in the TST period,
while in the QFT-GIT period either a positive QFT-GIT or a TST15 mm was required.
Measurements and main results
Six hundred and sixty-one contacts were compared. In the QFT-GIT period there was a
reduction in diagnoses of TB infection (77.4% vs. 51.2%; p <0.01) and preventive therapy
prescribed (62.1% vs. 48.2%; p = 0.02) among the 290 BCG-vaccinated contacts. After a
median follow-up of 5 years, cumulative incidences of TB were 0.62 and 0.29 in the TST
and QFT-GIT periods respectively (p = 0.59).
Conclusions
In BCG-vaccinated TB contacts, the addition of QFT-GIT safely reduced TB diagnosis and
treatment rates without increasing the risk of subsequent active TB.
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Introduction
Detection and treatment of recently infected people is an essential measure of tuberculosis
(TB) control in low-prevalence countries [1]. Up to approximately ten years ago, the diagnosis
of TB infection relied exclusively on the tuberculin skin test (TST). A positive TST response
indicates infection with Mycobacterium tuberculosis indirectly, by measuring the delayed-type
hypersensitivity response to the intradermal injection of a mixture of wall antigens, the so-
called PPD (purified protein-derivate), which is shared by many mycobacteria species and the
Bacillus Calmette–Gue´rin (BCG) strain [2]. The main limitations of the TST for targeting pre-
ventive therapy among the contacts of patients with pulmonary TB (TB contacts) are its low
specificity and poor ability to identify those likely to develop active disease [3]. Thus, a high
number of TB contacts need to be treated to prevent a case of TB in clinical practice.
By contrast to the TST, the interferon-γ release assays (IGRAs), the in vitro immunodiag-
nostic tests based on M. tuberculosis complex-specific antigens, have no cross-reactivity with
the BCG-vaccine strains and most non-tuberculous mycobacteria [4–6]. After more than a
decade, evidence indicates that, at best, the ability of these tests to predict the development of
TB is only a little better than that of the TST [7, 8]. Nevertheless, IGRAs yield fewer positive
results than TST, are more specific, and have shown a high negative predictive value for better
selecting those immunocompetent individuals who will not develop TB; thus, their use for tar-
geting TB contacts for preventive therapy, especially in BCG-vaccinated subjects, may still be
preferable to TST and also more cost-effective in certain settings [9].
In 2007, the QuantiFERON1-TB Gold In-tube (QFT-GIT) test was implemented in our
center. Shortly after, our TB Unit modified its internal protocol for contact tracing by adding
the QFT-GIT to the ongoing TST-based strategy for screening and informing treatment deci-
sions in BCG-vaccinated contacts of TB. Here, we report our experience with this practice. We
hypothesized that using the QFT-GIT to target TB contacts would reduce the number of indi-
viduals diagnosed with, and treated for, TB infection compared with the previous TST-only
strategy without an increased risk of subsequent active TB.
Methods
Design, setting, and study population
A retrospective comparative study of two screening strategies for TB contact tracing was per-
formed at the TB Unit of a teaching hospital for adults in Barcelona (Spain) between January
2006 and December 2010. The Ethics Committee of Bellvitge University Hospital approved
the study (PR269/11), and waived the need for consent. There was no specific survey questions
or questionnaire, as data was gathered as part of the standard assistance protocol.
We included immunocompetent contacts older than 15 years who had no history of TB
infection and whose index case had culture-proven non-MDR pulmonary TB. As part of rou-
tine clinical practice, medical histories, BCG-vaccination status (vaccine scar), treatment,
adverse events and adherence to therapy had been gathered prospectively.
Screening strategies and preventive therapy
We compared two consecutive 30-month periods: TST period (January 2006 to May 2008),
and QFT-GIT period (June 2008 to December 2010). In both periods, active TB was ruled out
through symptom-guided interview and chest X-ray. In the TST period there was no differ-
ence in contact management regarding BCG-vaccination status: the screening was performed
with TST, and non-responders underwent a second test after the window period (8 weeks). In
the absence of contraindications (p.e. pregnancy, liver disease), preventive therapy was
IGRAs in BCG-vaccinated contacts
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prescribed if TST was5 mm by 48–72 hours after administration. In the QFT-GIT period,
two different strategies were used according to BCG-vaccination status. While non-BCG con-
tacts were screened only with TST, as in the TST-period, BCG-vaccinated contacts were simul-
taneously screened using both the QFT-GIT assay and the TST. In this group preventive
therapy indication was established by either a positive QFT-GIT assay or a TST result15
mm. If the QFT-GIT assay was negative and the TST was <15 mm, a second QFT-GIT assay
was performed 8 weeks later. Two trained nurses checked BCG-vaccine status through its
characteristic scar and administered and read TST results. Treatment regimens included 6–9
months of treatment with isoniazid (INH) as the first-choice option, or 4 months with rifampi-
cin (RMP) or 3 months with RMP plus INH as alternative regimens. While on treatment, con-
tacts had regular appointments at the TB unit. There, both blood tests for monitoring liver
function and adherence assessments were carried out. The latter included the Eidus-Hamilton
test [10] for those taking INH and the simple checking of urine color for those on rifampicin.
Follow-up
In 2015, the vital status and development of TB were checked among all contacts by retrospec-
tive review of the electronic medical records of both the Hospital and local primary care ser-
vices, which were available online. If no data were available for the last 6 months or before the
contact completed at least 5 years of follow-up, individuals were contacted by phone and
briefly interviewed using a pre-designed questionnaire form. If the contact was not reachable,
they were considered lost to follow-up. Contacts were censored at the time of active TB diag-
nosis, death, loss to follow-up, or after 5 years of follow-up, whichever came first.
Data analysis
Incidence was given as the density of incidence (TB cases per person-time). Continuous vari-
ables were presented as medians (interquartile ranges) and compared with the Student t test or
the Mann–Whitney U rank test, as appropriate. Differences in categorical variables were
assessed with the χ2 test. All statistical analyses were two-tailed, and a p-value<0.05 was con-
sidered statistically significant. Analyses were performed with IBM1 SPSS1 Statistics for Mac-
intosh, Version 22.0 (IBM Corp., Armonk, NY; released 2013) and the OpenEpi software
(Open Source Epidemiologic Statistics for Public Health) [11].
Results
During the study period, 1395 contacts of 360 index cases were evaluated, and 661 were
included in the analysis (321 in the TST period and 340 in the QFT-GIT period). The selection
of eligible contacts is summarized in Fig 1, and the baseline characteristics of the cohort by
study period is shown in Table 1. The QFT-GIT period included a higher proportion of for-
eign-born individuals (p<0.01), close contacts (p<0.01), and BCG-vaccinated subjects
(p = 0.01).
TB Infection diagnosis and preventive therapy
Regarding diagnosis, 407 of 661 contacts (61.6%) were diagnosed with TB infection according
to the definition in each period (69.5% in the TST period and 54.1% in the QFT-GIT period; p
<0.01). Of the 290 BCG-vaccinated contacts in both periods, 181 (64.5%) were diagnosed with
TB infection (77.4% in the TST period and 51.2% in the QFT-GIT period; p<0.01). Table 2
shows the results of both tests for TB infection diagnosis in the 166 BCG-vaccinated patients
in the QFT-GIT period. As for the 371 non-BCG contacts, 226 (60.9%) were diagnosed with
IGRAs in BCG-vaccinated contacts
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TB infection, with no significant differences between periods (64.5% in the TST period and
56.9% in the QFT-GIT period; p = 0.14).
While there was a higher proportion of diagnosis of TB infection among BCG-vaccinated
contacts than among non-BCG-vaccinated contacts in the TST-period (77.4% and 64.5%
respectively; p = 0.01), there was no such difference in the QFT-GIT period, when TB infection
was diagnosed in 51.2% and 56.9% of BCG-vaccinated and non-BCG-vaccinated contacts
respectively; p = 0.29) (Fig 2).
As regards treatment, 357 courses of preventive treatment were prescribed. There were 50
contacts diagnosed with TB infection that were not recommended treatment: 37 (16.6%) and
13 (7%) in the TST and QFT-GIT-periods respectively. Eight contacts refused treatment. The
most common regimen was 6-month INH (n = 275), followed by INH for 9 months (n = 47),
rifampicin for 4 months (n = 19), and combination therapy with INH-RMP for 3 months
(n = 8). Among the 330 INH-based regimens, 19 individuals (5.8%) developed toxicity and
required drug withdrawal; 14 of them (73.7%) completed treatment with RMP. Overall, 290
(81.2%) contacts completed a whole course of treatment (77.9% and 87.1% in the TST and
QFT-GIT periods, respectively, p = 0.02). The higher proportion of lost to follow-up as well as
rejection or early withdrawal of preventive treatment in the first period was associated to non-
family ties with the index case (OR 2.63 [CI95% 1.43–4.84]).
Fig 1. Chart of the contacts included. TB: tuberculosis; HIV: human immunodeficiency virus; MDR: multi-
drug resistant; ESRD: end-stage renal disease; TST: tuberculin skin test; NTM: Non-tuberculous
mycobacteria. a12 and 6 patients in the first and second period, respectively.
https://doi.org/10.1371/journal.pone.0183258.g001
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Development of active tuberculosis
The outcomes of the 661 contacts are shown in Table 3. Information was retrievable from the
electronic medical records for 616 (93.2%) individuals, and another 45 (6.8%) were contacted
by phone.
Over the median follow-up period of 5 years, three contacts developed active TB: two
screened in the TST period and one screened in the QFT-GIT period. Table 4 shows their
main features.
Discussion
The results of this observational study support our hypothesis that the use of QFT-GIT for tar-
geting BCG-vaccinated TB contacts for preventive therapy is as effective as a TST-based
Table 1. Baseline characteristics and immunodiagnostic test results by study period.
TST period (n = 321) QFT-GIT period (n = 340) p
Gender, man; n (%) 151 (47.0) 157 (46.2) 0.82
Age; median (IQR) 37 (25.5–48.5) 33.5 (21–46) 0.08
Foreign-born; n (%) 72 (22.4) 148 (43.5) <0.01
-Latin America; n (% of foreign-born) 40 (55.6) 94 (63.5) - -
-North Africa 9 (12.5) 22 (14.9) - -
-Sub-Saharan Africa 1 (1.4) 15 (10.2) - -
-India/Pakistan 1 (1.4) 12 (8.1) - -
-South-East Asia 3 (4.2) 2 (1.4) - -
-Eastern Europe 18 (25) 3 (2) - -
Close contacta; n (%) 170 (53.0) 222 (65.3) <0.01
Family ties with index case; n (%) 268 (83.5) 238 (70) <0.01
Index case with positive smear; n (%) 229 (71.3) 228 (67.1) 0.24
BCG-vaccination; n (%) 124 (38.6) 166 (48.8) 0.01
1st TST-positiveb; n (%) 194 (60.4) 168 (49.4) <0.01
TB infection diagnosis; n (%) 223 (69.5) 184 (54.1) <0.01
BCG-vaccinated 96/124 (77.4) 85/166 (51.2) <0.01
Non-BCG-vaccinated 127/197 (64.5) 99/174 (56.9) 0.14
Preventive therapy prescribed; n (%) 186 (57.9) 171 (50.3) 0.05
IQR: interquartil range, BCG: Bacillus Calmette-Gue´rin, TST: tuberculin skin test.
a Exposure to the index case was stratified as close (household or daily6 hours of exposure), frequent (daily <6 hours of exposure), and occasional (no
household or daily exposure, and <2 hours of exposure each time).
b 1st TST refers to the first TST result. If negative, a second test was carried out after the window period, established as 8 weeks.
https://doi.org/10.1371/journal.pone.0183258.t001
Table 2. TST and QFT-GIT results of BCG-vaccinated patients in the second period.
QFT-GIT
Positive Negative
TST Positive 55(40 (73%) patients with TST 15 mm) 44(21 (48%) patients with TST15 mm) 99
Negative 9 58 67
64 102 166
TST: tuberculin skin test; QFT-GIT: QuantiFERON®-TB Gold In-Tube.
https://doi.org/10.1371/journal.pone.0183258.t002
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strategy for preventing subsequent development of TB, while allowing a substantial reduction
of treatment prescriptions.
In 2008, we found that we were treating a huge proportion of BCG-vaccinated individuals
(three out of every four contacts), and therefore decided to update the screening strategy. In
June of that year we introduced the QFT-GIT assay as part of our routine assessment of BCG-
vaccinated TB contacts, in line with current knowledge at that time. Despite the conservative
approach of treating close contacts with TST15 mm and negative QFT result, we attained a
significant reduction of 26% in TB diagnoses among BCG-vaccinated contacts, without
increasing the risk of active TB. This outcome is consistent with the findings of longitudinal
studies in other countries with low and intermediate incidences of TB and high vaccination
rates [12–14]. Although the effect of BCG vaccination on the TST’s specificity should not last
over 10 years if BCG was received in infancy, as it used to until 1978 in Spain, and BCG would
unlikely have a major influence in TST results in adults [15], obvious differences have been
reported to date in TST results and BCG vaccination status [16].
Fig 2. Proportion of TB infection diagnosis by study period and BCG-vaccination status.
https://doi.org/10.1371/journal.pone.0183258.g002
Table 3. Final disposition and incidence of active TB by study period.
TST period (N = 321) QFT-GIT period (N = 340) p
Dieda 11 13 0.79
Lost to follow-up before 5 years 14 54 <0.01
Median follow-up, years (IQR) 3.5 (2.0–4.2) 3.6 (2.7–4.4) 0.5
Median (IQR) follow-up, years (5 years
maximum) b
5 (N.A) 5 (4.9–5.0)
Patient-years 1581.84 1595.15
Incident TB cases 2 1 0.96
Cumulative incidence, % 0.62 0.29 0.59
Density of incidence,(TB cases x 1 000
p-years (95%CI))
1.26 (0.21–4.18) 0.63 (0.03–3.09) 0.62
TB: tuberculosis. TST: tuberculin skin test; QFT-GIT: QuantiFERON®-TB Gold In-Tube.
N.A: non-applicable.
a Died of non-TB related causes.
b5 years maximum.
https://doi.org/10.1371/journal.pone.0183258.t003
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In a German study of close contacts of smear-positive TB patients (n = 954), of the 495
BCG-vaccinated contacts who were TST-positive, 83% were5 mm and 31% were10 mm,
while only 17% had a positive QFT-GIT assay result [12]. After at least two years of follow-up,
none of the 413 TST-positive/QFT-GIT-negative untreated contacts had developed active TB.
In a French study of 687 TB contacts, of the 300 TST-positive contacts (10 mm), only 106
(35%) had positive QFT-GIT results [13]. Two contacts developed active TB after 3 years, one
of whom had a discordant TST-positive/QFT-GIT-negative result (negative predictive value
for the QFT-GIT assay of 99.8%). In another retrospective study from South Korea, which
included 1826 high-school student contacts, of the 270 TST-positive contacts (10 mm), 203
(75%) had positive QuantiFERON-Gold (QFT-G) results, but none of the 67 TST-positive/
QFT-G-negative untreated contacts progressed to active TB [14]. Conversely, a Dutch study,
which included foreign-born close contacts of smear-positive TB patients with high BCG-vac-
cination rates (81%), showed that using the QFT-GIT assay for preventive therapy decision,
resulted in three missed contacts who had positive TST results and subsequently progressed to
active TB [17]. However, in that study, QFT-GIT was performed only once, and shortly after
the diagnosis of the index case. Therefore, it is plausible that these cases could have been cap-
tured if retested a few weeks later.
Despite the reported differences, the results of the present and the three previous studies
indicate that the QFT-GIT assay is safe for targeting preventive therapy to fewer contacts. As
for cost-effectiveness in contact screening, the benefits of applying QFT-GIT as either a confir-
matory test or in place of the TST is also currently unknown. Some health economic models
have explored this issue. Given the similar sensitivities of QFT-GIT and TST for TB infection
in immunocompetent individuals and the higher specificity of QFT-GIT, despite its higher
testing costs, some models indicate that IGRA-based strategies might be the most cost-effective
option when a high pre-test probability is expected (>59%) [18]. However, in cases where the
estimated probability is lower, performing the QFT-GIT only in TST-positive contacts would
probably be most cost-effective, as it would significantly reduce the number of QFT-GIT tests,
and thus the overall testing costs. In our study, the BCG-vaccinated group in the second period
increased from 38% to almost half the cohort of contacts; the saving of 26% of preventive ther-
apies, blood tests and follow-up visits, as well as the avoidance of unnecessary risk, justify the
change in the protocol.
Table 4. Descriptive features of the TB cases diagnosed during the follow-up period.
TST period QFT-GIT period
Time from the first TB
infection screening (years)
4.5 4.2 3.3
Epidemiologic data Man, 51. Spanish Woman, 22. Bolivian Woman, 26. Spanish
BCG-vaccination Yes Yes No
Relationship with the index
case
Occasional relationship Close contact Close contact
TB infection screening No TB infection: Negative TST
(repeated after the window period) No
treatment.
TB infection: Positive TST (16
mm). TB preventive treatment.
TB infection: Positive TST (13 mm): switched from
negative after the window period). TB preventive
treatment.
Risk factor for developing
TB
No risk factors Abandoned preventive
treatment in the first month
(pregnancy)
Lack of adherence to treatment (6-month
isoniazid)
Form of TB Pulmonary (upper lobes) Pulmonary (upper lobes) Pulmonary (upper lobes)
BCG: Bacillus Calme´tte-Guerin; IC: Index case; TST: tuberculin skin test; TB: tuberculosis.
https://doi.org/10.1371/journal.pone.0183258.t004
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The present study also provides two relevant findings related to the screening and treatment
of TB infection among contacts. First, there was a non-negligible TB prevalence of 2.3% at the
time of the first appointment in the TB Unit among the 770 individuals with a recent infection
in our cohort (12 and 6 patients in each period, respectively); indeed, this confirms the impor-
tance of contact tracing for finding new cases and providing early treatment to avoid TB trans-
mission [19]. Second, a remarkably high proportion of individuals (81.2%) completed a full
course of preventive therapy without serious adverse events. In 5% of cases, foreseeable liver
toxicity was detected early and reversed by prompt drug withdrawal. Our experience confirms
that high completion rates are possible when well-trained staff deliver comprehensive health
education about treatment and toxicity following systematic interviews and providing written
information [20].
Although the single-center design might theoretically be considered a limitation, in fact it is
one of the main strengths of the study because it guarantees the homogeneity of the series.
Since contacts were prospectively evaluated under the same clinical program, our results were
not biased by diverse diagnosis and treatment strategies. Indeed, it was the evaluating team
who treated the index cases and their contacts, prescribed preventive therapy, systematically
took active measures to promote and control adherence to treatment, and looked for the fol-
low-up of the contacts. While there are larger cohorts, they usually come from regional data-
bases or the fusion of several databases coming from regions with different TB prevalence,
with different diagnostic and therapeutic approaches and no complete data on BCG-vaccina-
tion [21]. This paper provides well-documented evidence on the secure saving of unnecessary
treatments of TB contacts after the implementation of an IGRA. Although differences in LTBI
diagnosis could be attributed to a difference in the cut-off of the TST (5 mm in the first period
and 15 mm in the second), QFT-GIT contributed in the decision-making by means of its high
negative predictive value [7].
The other strength of the study is the long-term assessment for TB development. These five
years of follow-up include the highest risk period for developing active TB after being infected,
which has been classically established in two years [22]. Had we chosen a two-year period, we
would have missed the three new cases of TB.
Despite its strengths, this study also has limitations that deserve further comment. First, the
retrospective design: development of active TB was evaluated by passive monitoring of con-
tacts, who were assessed by reviewing clinical charts and phone interviews. This may have
resulted in some missed cases of active disease, although specific features of TB (lack of men-
tion in clinical notes equals lack of active TB) and the fact that active cases would have been
referred to our Centre do make this unlikely. Moreover, we did a cross-match with the con-
tacts in our cohort and the detection-system of new TB cases in Catalonia from 2006 to 2015.
Second, there were differences in the follow-up at 5 years, probably because of the high pro-
portion of immigrants in the second period (45.9%), who went back to their countries as a
consequence of the economic crisis in our country. However, the mean follow-up period was
almost 4 years (3.99; SD 1.08), which means that most of the high-risk period of developing TB
was passed before leaving Spain. Third, there were very few contacts that progressed to active
in both periods; as a consequence, wide confidence intervals impaired a proper comparison of
TB incidence between the two periods. Fourth, since we did not genotype the causative strain
of the three “assumed” cases of incident secondary TB, we cannot exclude the possibility of
reinfection by a different strain.
In conclusion, the results of this study add evidence on the benefit of implementing
QFT-GIT to target BCG-vaccinated contacts for preventive therapy. This approach reduces
exposure to unnecessary treatment without increasing the risk of subsequent active TB. Pro-
spective cohort studies with health economic data are needed to determine whether this
IGRAs in BCG-vaccinated contacts
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strategy is suitable and cost-effective for the management of non-BCG-vaccinated contacts,
and other risk groups for active TB.
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